Residency · Los Angeles, CA
Sponsored by UCLA David Geffen School of Medicine/UCLA Medical Center
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
JAMA oncology · 2023 · 270 citations · Amar Kishan, Martin Ma, Nicholas Nickols, Michael Steinberg
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 226 citations · Amar Kishan
Engineering protein-based therapeutics through structural and chemical design.
Nature communications · 2023 · 283 citations · Sasha Ebrahimi
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 289 citations · Dominique Rash
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Lancet (London, England) · 2024 · 251 citations ·
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
The New England journal of medicine · 2025 · 95 citations · Susan McCloskey
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Lancet (London, England) · 2026 · 35 citations · Christian Hyde
Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 80 citations · Puja Venkat